{"id":411548,"date":"2021-01-11T02:20:05","date_gmt":"2021-01-11T07:20:05","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411548"},"modified":"2021-01-11T02:20:05","modified_gmt":"2021-01-11T07:20:05","slug":"hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/","title":{"rendered":"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>\n          <b>Commercial launch activities for Idefirix<sup>\u00ae<\/sup>\u00a0progressing as planned<\/b>\n        <\/li>\n<li>\n          <b>Patient recruitment in the two phase 2 studies in AMR and GBS was reinitiated in <span class=\"xn-chron\">December 2020<\/span><\/b>\n        <\/li>\n<li>\n          <b>Year-end cash position of <span class=\"xn-money\">SEK 1.4 billion<\/span><\/b>\n        <\/li>\n<\/ul>\n<p>\n        <span class=\"xn-location\">LUND, Sweden<\/span>, <span class=\"xn-chron\">Jan. 11, 2021<\/span> \/PRNewswire\/ &#8212; Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced a business update for the fourth quarter 2020 and certain preliminary, unaudited key financials for its financial year 2020.<\/p>\n<p>The Company will be participating in the JP Morgan Global Healthcare Conference in <span class=\"xn-location\">San Francisco<\/span> from <span class=\"xn-chron\">January 11 to 14, 2021<\/span>, with a corporate presentation on <span class=\"xn-chron\">Thursday, January 14<\/span>, at <span class=\"xn-chron\">7:30am EST<\/span>\/<span class=\"xn-chron\">13:30 CET<\/span>.<\/p>\n<p>\n        <b><br \/>\n          <u>COVID-19 pandemic<\/u><br \/>\n        <\/b><br \/>\n        <br \/>Hansa has an exciting year ahead with the Company&#8217;s first product being launched in <span class=\"xn-location\">Europe<\/span>. However, the global COVID-19 pandemic may still adversely impact Hansa Biopharma&#8217;s operational business and trial activities.\u00a0<\/p>\n<p>Hansa Biopharma continues to take measures to protect employees and take social responsibility during this global healthcare crisis, while working to limit the potential negative effects on its business.<\/p>\n<p>\n        <i>&#8220;Hansa enters the new year well positioned to execute successfully on our key priorities and objectives for 2021, which are to ensure the successful launch of Idefirix<sup>\u00ae<\/sup>\u00a0in leading transplantation centres in select European markets, initiate a randomized, controlled clinical study in the US to support a future filing of a BLA in the US, and continue the strong current momentum behind our efforts to advance our pipeline of drug candidates within auto-immune diseases and gene therapy&#8221;<\/i>\u00a0states <b>S\u00f8ren Tulstrup, President and CEO, <span class=\"xn-person\">Hansa Biopharma<\/span>.<\/b>\u00a0<\/p>\n<p>\n        <b>Business Update<\/b><br \/>\n        <br \/>\n        <b><br \/>\n          <u>Commercialization in <span class=\"xn-location\">Europe<\/span><\/u><br \/>\n        <\/b><br \/>\n        <br \/>Hansa Biopharma&#8217;s evolution into a fully integrated, commercial stage biopharmaceutical company took a major step forward in the third quarter 2020 following the conditional approval of Idefirix<sup>\u00ae<\/sup> (imlifidase) by the European Commission for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.<\/p>\n<p>Commercial launch activities are underway as planned. Depending on the impact of the escalating COVID-19 pandemic, it is expected that the first commercial patient will be treated with Idefirix<sup>\u00ae<\/sup> during the first quarter of 2021.<\/p>\n<p>During the fourth quarter of 2020, pricing for Idefirix<sup>\u00ae<\/sup> was published in the first markets and agreements around reimbursement with healthcare providers and payers are expected to be completed in the early launch countries throughout the course of 2021.\u00a0<br \/>\u2003<br \/><b><u>Randomized Controlled Trial in the US\u00a0<\/u><\/b><br \/>Hansa is in ongoing discussions with the U.S. Food and Drug Administration (FDA) around a proposed study protocol for a new, randomized controlled study of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients.<\/p>\n<p>Depending on the development of the escalating COVID-19 pandemic in <span class=\"xn-location\">the United States<\/span> and on the resulting impact on enrollment, the Company expects to complete enrollment of this study in 2022 enabling a potential Biologics License Application (BLA) submission by 2023 under the accelerated approval pathway.<\/p>\n<p>\n        <b><br \/>\n          <u>Clinical pipeline update\u00a0<\/u><br \/>\n        <\/b><br \/>\n        <br \/>GBS (Guillain Barr\u00e9 Syndrome)<\/p>\n<ul type=\"disc\">\n<li>Five out of 30 targeted patients with Guillain Barr\u00e9 Syndrome, GBS, have been \u00a0enrolled in a phase 2 study with imlifidase. The recruitment process to the phase 2 study was temporarily paused due to the COVID-19 pandemic and reinitiated in the fourth quarter 2020 as previously guided.<\/li>\n<\/ul>\n<p>Antibody Mediated Rejection (AMR)<\/p>\n<ul type=\"disc\">\n<li>Four of 30 targeted patients with active AMR episodes have been enrolled in a phase 2 study with imlifidase. The recruitment process to the phase 2 study was temporarily paused due to the COVID-19 pandemic and was reinitiated in the fourth quarter 2020 as previously guided.\u00a0<\/li>\n<\/ul>\n<p>Anti-Glomerular Basement Membrane (anti-GBM) antibody disease\u00a0<\/p>\n<ul type=\"disc\">\n<li>On <span class=\"xn-chron\">September 24, 2020<\/span>, positive high-level data was presented from the investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease with two-thirds of patients achieving dialysis independence six months after treatment. The positive data marked an important milestone for Hansa Biopharma&#8217;s expansion of imlifidase outside transplantation. <\/li>\n<li>Regulatory discussions with the European Medicines Agency (EMA) and FDA will be initiated to determine the regulatory path forward for imlifidase in anti-GBM.\u00a0<\/li>\n<\/ul>\n<p>\n        <b><br \/>\n          <u>Pre-clinical programs<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>NiceR next generation enzymes for repeat dosing<\/p>\n<ul type=\"disc\">\n<li>Development of Hansa&#8217;s next generation enzymes for repeat dosing is progressing according to plan and initiation of IND-enabling toxocology studies is expected to commence in the first half of 2021.\u00a0<\/li>\n<\/ul>\n<p>Imlifidase as pre-treatment ahead of gene therapy in DMD and LGMD<\/p>\n<ul type=\"disc\">\n<li>On <span class=\"xn-chron\">July 2, 2020<\/span>, Hansa announced an exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as a potential pre-treatment prior to the administration of gene therapy in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD).\u00a0 <\/li>\n<li>The partnership has progressed as planned and during the second half of 2020, Sarepta initiated ongoing pre-clinical investigations with imlifidase as a potential pre-treatment in the gene therapy setting. On <span class=\"xn-chron\">January 7<\/span>, Sarepta announced top-line results for part 1 of Study 102 evaluating SRP-9001, one of its investigational gene therapy candidates for the treatment of Duchenne Muscular Dystrophy. Imlifidase was not given to any patients in this study. For further information, please refer to <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3032731-1&amp;h=880174701&amp;u=http%3A%2F%2Fwww.sarepta.com%2F&amp;a=www.sarepta.com\" rel=\"nofollow noopener noreferrer\">www.sarepta.com<\/a>.\u00a0<\/li>\n<\/ul>\n<p>\n        <b>Key Financials (preliminary, unaudited)<\/b><br \/>\n        <br \/>For the financial year 2020, total Operating loss is expected to be approximately <span class=\"xn-money\">SEK 425 million<\/span>. As of <span class=\"xn-chron\">December 31, 2020<\/span>, the company had a cash position (including short-term investments) of approx. <span class=\"xn-money\">SEK 1.4 billion<\/span>, which is expected to finance Hansa&#8217;s operations into 2023.<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <i>SEK million<\/i><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Q4 2020<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\" \/>\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">FY 2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">SG&amp;A expenses<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">63<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\" \/>\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">202<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">R&amp;D expenses <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">53<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\" \/>\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">230<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Operating profit\/loss<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-108<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\" \/>\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">-425<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Cash and short-term investments Dec 31, 2020 <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,378<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\" \/>\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,378<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p>The fourth quarter 2020 interim report including condensed financial statements will be published on <span class=\"xn-chron\">February 4, 2021<\/span>.<\/p>\n<p>\n        <b>CONTACT: <\/b>\n      <\/p>\n<p>\n        <b>For further information, please contact:<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Klaus Sindahl<\/span>, Head of Investor Relations<br \/>Hansa Biopharma\u00a0<br \/>Mobile: +46 (0) 709-298 269<br \/>E-mail: <a target=\"_blank\" href=\"mailto:klaus.sindahl@hansabiopharma.com\" rel=\"nofollow noopener noreferrer\">klaus.sindahl@hansabiopharma.com<\/a> \u00a0<\/p>\n<p>\n        <span class=\"xn-person\">Katja Margell<\/span><br \/>\n        <br \/>Head of Corporate Communications\u00a0<br \/>Hansa Biopharma\u00a0<br \/>Mobile: +46 (0) 768-198 326<br \/>E-mail: <a target=\"_blank\" href=\"mailto:katja.margell@hansabiopharma.com\" rel=\"nofollow noopener noreferrer\">katja.margell@hansabiopharma.com<\/a><\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3032731-1&amp;h=3141154905&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3032731-1&amp;h=1876392155&amp;u=https%3A%2F%2Fnews.cision.com%2Fhansa-biopharma-ab%2Fr%2Fhansa-biopharma-provides-business-update-incl--certain-key-financials-ahead-of-the-jp-morgan-global-%2Cc3265704&amp;a=https%3A%2F%2Fnews.cision.com%2Fhansa-biopharma-ab%2Fr%2Fhansa-biopharma-provides-business-update-incl--certain-key-financials-ahead-of-the-jp-morgan-global-%2Cc3265704\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/hansa-biopharma-ab\/r\/hansa-biopharma-provides-business-update-incl&#8211;certain-key-financials-ahead-of-the-jp-morgan-global-,c3265704<\/a>\n      <\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3032731-1&amp;h=2860938091&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F1219%2F3265704%2F1357442.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F1219%2F3265704%2F1357442.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/1219\/3265704\/1357442.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Release<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO44087&amp;sd=2021-01-11\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference-301204955.html\">http:\/\/www.prnewswire.com\/news-releases\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference-301204955.html<\/a><\/p>\n<p>SOURCE  Hansa Biopharma AB<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO44087&amp;Transmission_Id=202101110216PR_NEWS_USPR_____IO44087&amp;DateId=20210111\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Commercial launch activities for Idefirix\u00ae\u00a0progressing as planned Patient recruitment in the two phase 2 studies in AMR and GBS was reinitiated in December 2020 Year-end cash position of SEK 1.4 billion LUND, Sweden, Jan. 11, 2021 \/PRNewswire\/ &#8212; Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced a business update for the fourth quarter 2020 and certain preliminary, unaudited key financials for its financial year 2020. The Company will be participating in the JP Morgan Global Healthcare Conference in San Francisco from January 11 to 14, 2021, with a corporate presentation on Thursday, January 14, at 7:30am EST\/13:30 CET. COVID-19 pandemic Hansa has an exciting year ahead with the Company&#8217;s first product &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411548","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Commercial launch activities for Idefirix\u00ae\u00a0progressing as planned Patient recruitment in the two phase 2 studies in AMR and GBS was reinitiated in December 2020 Year-end cash position of SEK 1.4 billion LUND, Sweden, Jan. 11, 2021 \/PRNewswire\/ &#8212; Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced a business update for the fourth quarter 2020 and certain preliminary, unaudited key financials for its financial year 2020. The Company will be participating in the JP Morgan Global Healthcare Conference in San Francisco from January 11 to 14, 2021, with a corporate presentation on Thursday, January 14, at 7:30am EST\/13:30 CET. COVID-19 pandemic Hansa has an exciting year ahead with the Company&#8217;s first product &hellip; Continue reading &quot;Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T07:20:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO44087&amp;sd=2021-01-11\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference\",\"datePublished\":\"2021-01-11T07:20:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/\"},\"wordCount\":964,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO44087&amp;sd=2021-01-11\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/\",\"name\":\"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO44087&amp;sd=2021-01-11\",\"datePublished\":\"2021-01-11T07:20:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO44087&amp;sd=2021-01-11\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO44087&amp;sd=2021-01-11\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference - Market Newsdesk","og_description":"PR Newswire Commercial launch activities for Idefirix\u00ae\u00a0progressing as planned Patient recruitment in the two phase 2 studies in AMR and GBS was reinitiated in December 2020 Year-end cash position of SEK 1.4 billion LUND, Sweden, Jan. 11, 2021 \/PRNewswire\/ &#8212; Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced a business update for the fourth quarter 2020 and certain preliminary, unaudited key financials for its financial year 2020. The Company will be participating in the JP Morgan Global Healthcare Conference in San Francisco from January 11 to 14, 2021, with a corporate presentation on Thursday, January 14, at 7:30am EST\/13:30 CET. COVID-19 pandemic Hansa has an exciting year ahead with the Company&#8217;s first product &hellip; Continue reading \"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T07:20:05+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO44087&amp;sd=2021-01-11","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference","datePublished":"2021-01-11T07:20:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/"},"wordCount":964,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO44087&amp;sd=2021-01-11","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/","name":"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO44087&amp;sd=2021-01-11","datePublished":"2021-01-11T07:20:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO44087&amp;sd=2021-01-11","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO44087&amp;sd=2021-01-11"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411548"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411548\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}